Meeting
2020 Gastrointestinal Cancers Symposium
Cobimetinib plus vemurafenib (C+V) in patients (Pts) with colorectal cancer (CRC) with BRAF V600E mutations: Results from the TAPUR Study.
Authors
Kelsey Klute
University of Nebraska Medical Center, Omaha, NE
Kelsey Klute , Elizabeth Garrett-Mayer , Susan Halabi , Pam K. Mangat , Reza Nazemzadeh , Kathleen J Yost , Nicole L. Butler , Venu Perla , Richard L. Schilsky
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Anal and Colorectal Cancer
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02693535
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 122)
Abstract #
122
Poster Bd #
F8
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Temsirolimus (T) in patients (pts) with colorectal cancer (CRC) with PIK3CA mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
First Author: Jean L. Grem
Poster
2020 Gastrointestinal Cancers Symposium
Pembrolizumab (P) in patients (Pts) with colorectal cancer (CRC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
First Author: Eyal Meiri
Poster
2022 ASCO Annual Meeting
Temsirolimus (T) in patients (pts) with solid tumors with mTOR mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
First Author: Gordan Srkalovic